University of Health Sciences, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Department of Rheumatology, Turkey.
Med Hypotheses. 2019 Sep;130:109269. doi: 10.1016/j.mehy.2019.109269. Epub 2019 Jun 10.
Colchicine is the first choice of the treatment in familial Mediterranean fever (FMF). However, in FMF patients with amyloidosis, especially during creatinine level >1.5 mg/dL and nephrotic range proteinuria, colchicine may be ineffective. Interleukin-1 (IL-1) blockers could be used in colchicine resistant cases. However, starting IL-1 blocker treatment after colchicine failure may lose opportunity for effective treatment. Therefore, administering IL-1 blocker together with colchicine as first line therapy may increase the chance for suppressing the disease.
秋水仙碱是家族性地中海热（FMF）治疗的首选药物。然而，在患有淀粉样变性的 FMF 患者中，特别是在肌酐水平>1.5mg/dL 和肾病范围蛋白尿时，秋水仙碱可能无效。白细胞介素-1（IL-1）阻滞剂可用于秋水仙碱耐药的病例。然而，在秋水仙碱治疗失败后开始使用 IL-1 阻滞剂治疗可能会错失有效治疗的机会。因此，将 IL-1 阻滞剂与秋水仙碱联合作为一线治疗可能会增加抑制疾病的机会。
